XML 87 R4.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated balance sheets - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Non-current assets [abstract]    
Property, plant and equipment $ 12,263 $ 12,069
Right-of-use assets 1,676 1,677
Goodwill 29,999 26,524
Intangible assets other than goodwill 36,809 28,787
Investments in associated companies 9,632 8,644
Deferred tax assets 8,214 7,909
Financial assets 2,901 2,518
Other non-current assets 892 738
Total non-current assets 102,386 88,866
Current assets [abstract]    
Inventories 7,131 5,982
Current trade receivables 8,217 8,301
Income tax receivable 239 254
Marketable securities, commodities, time deposits and derivative financial instruments 1,905 334
Cash and cash equivalents 9,658 11,112
Other current assets 2,523 2,680
Total current assets without disposal group 29,673 28,663
Assets of disposal group held for sale   841
Total current assets 29,673 29,504
Total assets 132,059 118,370
Equity [abstract]    
Share capital 913 936
Treasury shares (53) (80)
Reserves 55,738 54,618
Equity attributable to Novartis AG shareholders 56,598 55,474
Non-controlling interests 68 77
Total equity 56,666 55,551
Non-current liabilities [abstract]    
Financial debts 26,259 20,353
Lease liabilities 1,719 1,703
Deferred tax liabilities 7,422 5,867
Provisions and other non-current liabilities 6,934 6,632
Total non-current liabilities 42,334 34,555
Current liabilities [abstract]    
Trade payables 5,403 5,424
Financial debts and derivative financial instruments 9,785 7,031
Lease liabilities 286 246
Current income tax liabilities 2,458 2,194
Provisions and other current liabilities 15,127 13,338
Total current liabilities without disposal group 33,059 28,233
Liabilities of disposal group held for sale   31
Total current liabilities 33,059 28,264
Total liabilities 75,393 62,819
Total equity and liabilities $ 132,059 $ 118,370